| Serial Number | 97766160 |
| Word Mark | BIBAX |
| Filing Date | Tuesday, January 24, 2023 |
| Status | 653 - SUSPENSION LETTER - MAILED |
| Status Date | Wednesday, January 31, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Medical and veterinary preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment and prevention of human infectious diseases; biomedical pharmaceutical products for the treatment and prevention of human infectious diseases; clinical diagnostic reagents; therapeutic agents being Therapeutic vaccines; prophylactical agent substances, namely, pharmaceutical preparations for the prevention of infectious diseases; medicine being Medicinal preparations for the treatment of infectious diseases and for use in; biological and chemical reagents, for medical and veterinary uses; agonists for medical and veterinary uses, namely, namely, pharmaceutical preparations for the treatment and prevention of human infectious diseases; medicines for veterinary purposes for the treatment and prevention of infectious diseases; amino acids for medical or veterinary purposes; antibacterial pharmaceuticals; anti-bacterial preparations; antibacterial substances for medical purposes; antigens, namely, pharmaceutical preparations for the treatment and prevention of infectious diseases; antibodies, namely, monoclonal antibodies for in vivo or clinical use; antitoxins; antiviral drugs for treating influenza; antiviral drugs for treating hiv; anti-viral agents, namely, anti-viral antigens being pharmaceutical preparations for the treatment and prevention of infectious diseases; autoantigens, namely, pharmaceutical preparations for the treatment and prevention of human autoimmune diseases and cancer; biological adjuvants for medical purposes; endogenous antigens, namely, pharmaceutical preparations for the treatment and prevention of human autoimmune diseases and cancer; exogenous antigens, namely, pharmaceutical preparations for the treatment and prevention of infectious diseases; human immune globulin for the treatment and prevention of cancer and infectious diseases; human vaccine preparations; immunomodulators; immunostimulants; vaccines against flu; immunotherapeutic agents for bacterial infections; anti-infective goods for medical and veterinary uses; medicated mouth spray; medicated nasal spray preparations; anti-malarials; neoantigens, namely, pharmaceutical preparations for the treatment and prevention of cancer; pharmaceutical products for treating respiratory diseases, pharmaceutical products for the treatment of infectious diseases, pharmaceutical preparations for the treatment of autoimmune disorders, pharmaceutical preparations for the treatment of disorders caused by bacteria, pharmaceutical preparations for the treatment of diseases caused by bacteria, pharmaceutical preparations for the treatment of autoimmune disorders, pharmaceutical preparations for the treatment of viral diseases; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the prevention of diseases caused by bacteria; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of disorders of the immune system; anti-infectives; anti- tuberculous preparations; tumour antigens, namely, pharmaceutical preparations for the treatment and prevention of cancer; viral antigens, namely, pharmaceutical preparations for the treatment and prevention of infectious diseases; viral vaccines; veterinary vaccines; vaccines; mrna and vector-based vaccines; protein-based vaccines |
| Goods and Services | Provision of information and data in the field of medical and veterinary research and development, namely, in the fields of immunology, infectiology and vaccines; research and design for the pharmaceutical industry, namely in the fields of immunology, infectiology and vaccines; biomedical research services; research and development in the field of vaccines; software development and research in the fields of infectiology and immunology; research and development of biomolecules, cells and cell products for medical purposes; research and development of biomedical goods, in particular therapeutic and prophylactic substances, namely, pharmaceuticals for medical purposes, and preparations for the treatment of Coronaviridae, including SARS-CoV-2 and MERS-CoV, Flaviviridae including Dengue, hepatitis, yellow fever, and Zika virus, Herpesviridae including EBV, Orthomyxoviridae including Influenzaviruses, and Filoviridae; medical laboratory services; computer diagnostic services |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, February 13, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, February 13, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | NOT AVAILABLE |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 01 - Individual |
| Address | Berlin D-10437 DE |
| Event Date | Event Description |
| Wednesday, January 31, 2024 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Wednesday, January 31, 2024 | LETTER OF SUSPENSION E-MAILED |
| Wednesday, January 31, 2024 | SUSPENSION LETTER WRITTEN |
| Friday, January 26, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, January 25, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, January 25, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, October 25, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, October 25, 2023 | NON-FINAL ACTION E-MAILED |
| Wednesday, October 25, 2023 | NON-FINAL ACTION WRITTEN |
| Saturday, October 21, 2023 | ASSIGNED TO EXAMINER |
| Monday, February 13, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, January 27, 2023 | NEW APPLICATION ENTERED |